All News

Neladalkib enters phase 3 trials, targeting advanced ALK-positive NSCLC, promising improved outcomes for TKI-naive patients with brain metastases.

Lessons from the past season could strengthen prevention and drive vaccinations for 2025-2026.

Omolola (Lola) Adeoye-Olatunde, PharmD, MS, discusses findings from a multi-year analysis of American Association of Colleges of Pharmacy (AACP) institutional data on faculty and graduate student representation in pharmacy education, highlighting persistent disparities and offering actionable strategies to improve equity and inclusion in the academic pipeline.

Nikita Dahake, MD; Hossein Borghaei, DO, MS; and Yasmine Baca, MS, PhD candidate, MB(ASCP)CM, explore how distinct HER2-alteration subtypes in non-small cell lung cancer (NSCLC) impact survival outcomes, co-mutation profiles, and treatment response to immunotherapy-based regimens.

Franck Morschhauser, MD, PhD, discusses the novel cereblon-dependent bifunctional degrader BMS-986458, highlighting its selective targeting of BCL6, promising early efficacy in relapsed/refractory lymphoma, favorable safety profile, and future potential in combination regimens and earlier treatment lines.

Influenza vaccination significantly reduces cases and enhances community immunity, highlighting pharmacists' vital role in promoting public health.

Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action.

Education initiatives, facilitation, and immunization on the part of pharmacists were found to significantly increase uptake of pneumococcal vaccines among older adults.

The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.

Long-term obesity accelerates aging in young adults, increasing risks for cardiovascular diseases and metabolic dysfunction.

ImCheck's ICT01 gains an orphan drug designation from the FDA, offering hope for acute myeloid leukemia (AML) treatment in older patients with limited options.

Researchers unveil a groundbreaking method using polypurine hairpins to inhibit PCSK9, offering a promising alternative for lowering cholesterol and reducing cardiovascular risk.

Immunocompromised patients, especially transplant recipients, face heightened RSV risks, leading to severe infections and complications.

The updated version 1.2026 NCCN Guidelines for chronic myeloid leukemia (CML) emphasize individualized treatment strategies, TKI-specific considerations, drug interaction management, and pregnancy safety, highlighting the critical role of oncology pharmacists in optimizing therapy selection, patient counseling, and cost-effective care.

The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing options, and streamlined Risk Evaluation and Mitigation Strategy program.

NCCN updates ovarian cancer guidelines, emphasizing personalized maintenance therapy with niraparib for HR-deficient patients, enhancing oncology pharmacists' roles.

The FDA recently approved gepotidacin oral tablets for the treatment of uncomplicated urinary tract infections (UTIs).

Unused, unwanted, and expired medications pose a serious threat to both public health and the environment.

GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.

UPMC's integrated approach to COPD care enhances patient outcomes through personalized support, coordinated services, and effective pulmonary rehabilitation strategies.

Enzalutamide combined with leuprolide significantly enhances survival in high-risk non-metastatic prostate cancer, marking a breakthrough in treatment strategies.

Unique barriers can lead to psychiatric medication adherence rates as low as 26%.

Pharmacists play a vital role in translating global health news into actionable knowledge for their communities.

Once-weekly efsitora alfa shows promising hemoglobin A1C reduction in type 2 diabetes (T2D), simplifying insulin therapy and reducing injection frequency significantly.

Research reveals HER2-negative breast cancer shows higher pCR rates than HER2-low, influencing neoadjuvant chemotherapy strategies for early-stage patients.

A large retrospective study funded by the CDC indicates broad additional protection against COVID-19, especially for older adults and immunocompromised patients.